Pinealon: Research Overview

Pinealon is a synthetic tripeptide designated EDR (Glu-Asp-Arg), originally isolated as an active fraction from Cortexin, a polypeptide drug derived from calf cortex and used in Russian clinical practice. Like other Khavinson bioregulators, the bulk of published research originates from a single laboratory — the St. Petersburg Institute of Bioregulation and Gerontology, led by Professor Vladimir Khavinson. Pinealon is not approved for any medical use by Western regulatory agencies, and as of 2026 no independent large-scale clinical trials have been published outside Russia.

What Is Pinealon?

Pinealon is a tripeptide consisting of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR in single-letter code). It is classified by the Khavinson group as a peptide bioregulator hypothesized to target the central nervous system and pineal gland. The compound is fully synthetic (not extracted from animal tissue) and is commercially available as a research compound from multiple vendors. Its molecular weight is approximately 390 Da, which is small enough for some researchers to hypothesize direct interaction with chromatin.

Mechanism

The proposed mechanism of Pinealon involves direct interaction with DNA regulatory elements. Khavinson and colleagues hypothesize that short peptide bioregulators can bind gene promoter regions and modulate transcription of proteins involved in neuroprotection and cellular maintenance. In cell culture studies, the EDR peptide was reported to reduce reactive oxygen species accumulation, decrease markers of neuronal apoptosis, and activate expression of proteins associated with neuronal functional activity. A 2021 MDPI publication (PMC7795577) proposed that EDR peptide modulates gene expression relevant to Alzheimer's disease pathogenesis, including effects on APP and BACE1 pathway regulators. This mechanism — a peptide directly influencing gene expression — is not well-established in mainstream molecular biology and requires independent validation.

What the Research Shows

Published studies on Pinealon span in vitro neuronal culture models, rodent models of oxidative stress and ischemia, and small observational studies in elderly humans. In a 2021 mouse model of Alzheimer's disease (MDPI Pharmaceuticals, doi:10.3390/ph14060515), the EDR peptide — alongside a related tripeptide KED — was reported to prevent dendritic spine loss in hippocampal neurons of 5xFAD mice, suggesting potential relevance to neuroplasticity preservation in early neurodegeneration. Human observational data from Khavinson’s group include reports of improved memory, attention, and mental performance in elderly subjects administered Cortexin (which contains EDR), but these studies are not controlled trials by independent investigators.

A 2022 paper in PMC (PMC9032300) characterized the neuroepigenetic mechanisms of ultrashort peptides including EDR in Alzheimer's disease models, providing a proposed mechanistic framework. All published clinical and near-clinical work is from the Khavinson laboratory. The absence of independent replication is a significant limitation for evaluating these claims.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published dose-finding studies are limited; values reported here come from Khavinson laboratory publications and have not been validated in modern clinical trials. Russian clinical literature references oral routes (tablet or sublingually dissolved peptide) at ranges of 5–10 mg per dose, typically in short courses. Animal studies have used subcutaneous routes. No peer-reviewed pharmacokinetic study establishing optimal human dosing for Pinealon as a standalone compound has been published in English-language literature as of 2026.

References

1. Khavinson V et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2021;26(1):159. PMC7795577.

2. Khavinson V et al. Neuroprotective Effects of Tripeptides — Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021;14(6):515. doi:10.3390/ph14060515.

3. Khavinson V et al. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. Int J Mol Sci. 2022;23(8):4259. PMC9032300.